This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Adverse Events Related to Olanzapine

Robert R. Conley, MD, and Herbert Y. Meltzer, MD

Published: May 30, 2000

Article Abstract

Olanzapine, a serotonin-dopamine receptor antagonist, is one of the novel atypical antipsychoticsthat is effective against the positive and negative symptoms of schizophrenia with significantly fewertreatment-emergent extrapyramidal symptoms and less akathisia associated with traditional antipsychotics.Compared with traditional agents, olanzapine shows only a few adverse events such as drymouth, sedation, and increase in appetite. Compared with risperidone, olanzapine causes greaterincreases in weight gain and body mass index but less hyperprolactinemia. Transient, non-dosedependent,asymptomatic elevations in liver enzymes have also been noted in olanzapine-treatedpatients. Because of the comparative efficacy and improved side effect profiles of the atypical antipsychotics,consideration should be given to using the newer agents as preferred treatment for schizophreniaand related psychoses.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 61

Quick Links: